Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466930 | 0.86 | HPGD (0.44) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL12467414 | 0.86 | HPGD (0.44) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL12468248 | 0.86 | HPGD (0.44) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL12468320 | 0.86 | HPGD (0.44) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL12401382 | 0.85 | EPHX2 (0.43) | HPGDKMT2AEPHX1EPHX2ALDH1A1 | |
| SCHEMBL12467386 | 0.84 | KMT2A (0.41) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL12467559 | 0.77 | EPHX1 (0.45) | EPHX1TSHRNPC1RAB9A | |
| SCHEMBL12330772 | 0.74 | HPGD (0.46) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL15219810 | 0.74 | HPGD (0.46) | HPGDKMT2AEPHX1EPHX2NPC1 | |
| SCHEMBL15219741 | 0.74 | HPGD (0.46) | HPGDKMT2AEPHX1EPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | HPGD 1824/4885KMT2A 2779/4885EPHX1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.